Physician profile
Daniel Wahlstrom
NPI 1265013619
$1,159.16
in general payments reported to CMS, 2019-2025
19 companies · $1,159 in 2025
The $1,159 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $1,159.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,159.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $286.02 | 2025 | |
| Novartis Pharmaceuticals Corporation | $109.51 | 2025 | |
| Ucb, INC. | $98.93 | 2025 | Zilbrysq, Rystiggo |
| Alexion Pharmaceuticals, INC. | $90.05 | 2025 | Ultomiris |
| Catalyst Pharmaceuticals, INC. | $62.01 | 2025 | |
| Tg Therapeutics, INC. | $60.95 | 2025 | |
| Lundbeck LLC | $59.07 | 2025 | Vyepti |
| Biogen, INC. | $56.46 | 2025 | Vumerity, Tysabri |
| Teva Pharmaceuticals USA, INC. | $49.73 | 2025 | Austedo Xr |
| Tms Neurohealth Centers INC. | $41.59 | 2025 | Tms Neurohealth Centers INC. |
| Csl Behring | $35.35 | 2025 | Hizentra |
| Takeda Pharmaceuticals U.S.A., INC. | $35.04 | 2025 | Hyqvia |
| Argenx US, INC. | $30.36 | 2025 | Vyvgart Hytrulo |
| Genentech USA, INC. | $26.74 | 2025 | Ocrevus Zunovo |
| Otsuka America Pharmaceutical, INC. | $26.64 | 2025 | Rexulti |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impel Pharmaceuticals LLC | $25.51 | 2025 | Trudhesa |
| Tonix Medicines, INC. | $24.30 | 2025 | Zembrace Symtouch |
| Janssen Biotech, INC. | $21.91 | 2025 | |
| Acadia Pharmaceuticals INC | $18.99 | 2025 | Nuplazid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Wahlstrom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.